The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trials
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the DREAMM-7 (NCT04246047) and DREAMM-8 (NCT04484623) trials, which have established belantamab mafodotin combinations as a potential new second-line standard of care (SoC) for multiple myeloma (MM). DREAMM-7 demonstrated the efficacy of belantamab mafodotin with bortezomib and dexamethasone, while DREAMM-8 showed its efficacy with pomalidomide and dexamethasone. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen, Sanofi, Regeneron, Celgene, Menarini, Takeda, GSK, BMS, Janssen, Beigene, Swixx, Astra Zeneca.
